LopesAA, AlbertJM, YoungEW, et al.: Screening for depression in hemodialysis patients: Associations with diagnosis, treatment, and outcomes in the DOPPS. Kidney Int, 2004; 66:2047–2053.
2.
KatonWJ: Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry, 2003; 54:216–226.
3.
HedayatiSS, BosworthHB, BrileyLP, et al.: Death or hospitalization of patients on chronic hemodialysis is associated with a physician-based diagnosis of depression. Kidney Int, 2008; 74:930–936.
4.
HedayatiSS, GrambowSC, SzczechLA, et al.: Physician-diagnosed depression as a correlate of hospitalizations in patients receiving long-term hemodialysis. Am J Kidney Dis, 2005; 46:642–649.
5.
Abdel-KaderK, UnruhML, WeisbordSD: Symptom burden, depression, and quality of life in chronic and end-stage kidney disease. Clin J Am Soc Nephrol, 2009; 4:1057–1064.
6.
LingC, EvansD, ZhangY, et al.: The effects of cognitive behavioural therapy on depression and quality of life in patients with maintenance haemodialysis: A systematic review. BMC Psychiatry, 2020; 20:369.
7.
NataleP, PalmerSC, RuospoM, et al.: Psychosocial interventions for preventing and treating depression in dialysis patients. Cochrane Database Syst Rev, 2019; 12:CD004542.
8.
SohnBK, OhYK, ChoiJ-S, et al.: Effectiveness of group cognitive behavioral therapy with mindfulness in end-stage renal disease hemodialysis patients. Kidney Res Clin Pract, 2018; 37:77–84.
9.
BirdeeGS, PhillipsRS, BrownRS: Use of complementary and alternative medicine among patients with end-stage renal disease. Evidence-Based Complementary and Alternative Medicine, 2013; 2013:654109.
10.
CukorD, Ver HalenN, AsherDR, et al.: Psychosocial intervention improves depression, quality of life, and fluid adherence in hemodialysis. J Am Soc Nephrol, 2014; 25:196–206.
11.
SiddiqueAB, KrebsM, AlvarezS, et al.: Mobile apps for the care management of chronic kidney and end-stage renal diseases: Systematic search in app stores and evaluation. JMIR Mhealth Uhealth, 2019; 7:e12604.
12.
PalmerSC, NataleP, RuospoM, et al.: Antidepressants for treating depression in adults with end-stage kidney disease treated with dialysis. Cochrane Database Syst Rev, 2016; 23:CD004541.
13.
WangS-M, HanC, BahkW-M, et al.: Addressing the side effects of contemporary antidepressant drugs: A comprehensive review. Chonnam Med J, 2018; 54:101–112.
14.
HedayatiSS, YalamanchiliV, FinkelsteinFO: A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease. Kidney Int, 2012; 81:247–255.
15.
Pena-PolancoJE, MorMK, TohmeFA, et al.: Acceptance of antidepressant treatment by patients on hemodialysis and their renal providers. Clin J Am Soc Nephrol, 2017; 12:298–303.
16.
ShirazianS, GrantCD, AinaO, et al.: Depression in chronic kidney disease and end-stage renal disease: Similarities and differences in diagnosis, epidemiology, and management. Kidney Int Rep, 2017; 2:94–107.
17.
NaglerEV, WebsterAC, VanholderR, ZoccaliC: Antidepressants for depression in stage 3–5 chronic kidney disease: A systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrol Dialysis Transplant, 2012; 27:3736–3745.
18.
KollaBP, MansukhaniMP, BostwickJM: The influence of antidepressants on restless legs syndrome and periodic limb movements: A systematic review. Sleep Med Rev, 2018; 38:131–140.
19.
PakfetratM, MalekmakanL, HashemiN, TadayonT: Sertraline can reduce uremic pruritus in hemodialysis patient: A double blind randomized clinical trial from Southern Iran. Hemodialysis Int Sympos Home Hemodialysis, 2018; 22:103–109.
20.
LoboED, HeathmanM, KuanHY, et al.: Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: Analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials. Clin Pharmacokinet, 2010; 49:311–321.
21.
EylerRF, UnruhML, QuinnDK, Mary Vilay A (eds): Psychotherapeutic agents in end-stage renal disease. Semin Dial, 2015; 28:417–426.
22.
WorrallSP, AlmondMK, DhillonS: Pharmacokinetics of bupropion and its metabolites in haemodialysis patients who smoke. A single dose study. Nephron Clin Pract, 2004; 97:c83–c89.
23.
DemyttenaereK, JaspersL: Bupropion and SSRI-induced side effects. J Psychopharmacol, 2008; 22:792–804.
